SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluxion Biosciences, a leading provider of cell analysis platforms for research and diagnostics, today announced that it has won a 2013 R&D 100 Award for its IsoFlux™ System. The R&D 100 Award places the state-of-the-art IsoFlux System in the prestigious company of previous winners such as liquid crystal displays and the anticancer drug Taxol.
Known as "the Oscars of Innovation", the R&D 100 Award showcases the most significant new technologies worldwide. This year, R&D Magazine recognized Fluxion’s IsoFlux system for its ability to perform a "liquid biopsy" on a cancer patient by analyzing a patient’s cancer markers from a simple blood draw. Based on Fluxion’s novel microfluidics, the IsoFlux system isolates, purifies, and recovers circulating tumor cells at levels that weren’t previously possible. Complete analytical workflows are available to detect genomic mutations, gene expression profiles, protein expression, and chromosomal abnormalities.
Introduced in 2012, the IsoFlux system is used globally by leading drug developers and cancer research institutes including Bayer, Ingham Institute, University of Dusseldorf, Stanford, and many others. The system is being used for a number of applications, including clinical trial patient testing, longitudinal monitoring of patients during treatment, and as a replacement for tissue in hard-to-biopsy cancers such as lung and pancreas.
"We are honored to be recognized by R&D Magazine for the IsoFlux System and to be ranked among the world's top technology innovators," said Mike Schwartz, IsoFlux Program Director. "There is a critical need to deliver on the promise of personalized medicine in cancer by identifying the right treatment for each patient using simple, non-invasive methods. With the introduction of IsoFlux, researchers and clinicians now have a tool that allows molecular analysis on circulating tumor cells without invasive procedures. Our customers are actively using the system to develop new diagnostics and treatments that will improve the lives of cancer patients everywhere."
Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Fluxion’s proprietary microfluidic platform enables precise functional analysis of individual cells in a multiplexed format. Products include the BioFlux™ System for studying cellular interactions, the IonFlux™ System for high throughput patch clamp measurements, and the IsoFlux™ System for circulating tumor cells. Fluxion’s systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information about Fluxion Biosciences, visit www.fluxionbio.com.
